Introduction
============

Kallmann syndrome (KS) is a developmental disease that associates hypogonadotropic hypogonadism, due to gonadotropin-releasing hormone (GnRH) deficiency, and anosmia, related to the absence or hypoplasia of the olfactory bulbs (Kallmann, [@B22]; deMorsier, [@B9]; Naftolin et al., [@B38]). The degree of the hypogonadism and that of the smell deficiency can vary significantly, not only between unrelated KS patients, but also between patients from the same family. The prevalence of KS has been estimated at one out of 8000 in boys. In girls, the prevalence is thought to be five times lower, but it is probably underestimated because some affected females only have mild hypogonadism, and also because primary amenorrhea in females often remains unexplored (Jones and Kemmann, [@B19]).

Pathohistological studies of fetuses with olfactory bulb agenesis have shown that the reproductive phenotype of KS results from a pathological sequence in embryonic life, whereby premature interruption of the olfactory, vomeronasal, and terminal nerve fibers in the frontonasal region disrupts the migration of neuroendocrine GnRH cells, which normally migrate from the nose to the brain along these nerve fibers (Schwanzel-Fukuda and Pfaff, [@B47]; Teixeira et al., [@B52]). What causes the primary failure of these fibers to establish proper contact with the forebrain is, however, still unknown.

Kallmann syndrome is genetically heterogeneous and involves various modes of transmission, specifically, X-chromosome linked, autosomal recessive, autosomal dominant with incomplete penetrance, and also digenic/oligogenic inheritance (Dodé and Hardelin, [@B10]; Sykiotis et al., [@B51]). Because the common infertility in affected individuals and, most importantly, the incomplete penetrance of the disease impede genetic linkage analysis, researchers have used various strategies to identify genes involved in KS, including mutation screening in genes that are disrupted by deletion or translocation breakpoints in chromosomal rearrangements associated with the disease phenotype, and candidate gene approaches. Nine causal genes have been reported to date, namely, by chronological order of discovery, *KAL1* (Franco et al., [@B14]; Legouis et al., [@B27]; Hardelin et al., [@B17]), *FGFR1* (Dodé et al., [@B11]), *PROKR2* and *PROK2* (Dodé et al., [@B12]), *FGF8* (Falardeau et al., [@B13]), *CHD7* (Kim et al., [@B25]; Jongmans et al., [@B20]), *WDR11* (Kim et al., [@B24]), *HS6ST1* (Tornberg et al., [@B53]), and *SEMA3A* (Hanchate et al., [@B16]; Young et al., [@B55]) (Table [1](#T1){ref-type="table"}). Various loss-of-function mutations in *KAL1*, encoding the extracellular matrix glycoprotein anosmin-1, and in *FGFR1* or *FGF8*, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, underlie the X-chromosome linked form and an autosomal dominant form of KS, respectively. Mutations in *KAL1* and *FGFR1/FGF8* account for roughly 8 and 10% of all KS cases, respectively. The *KAL1* gene product, anosmin-1, binds to heparan-sulfate glycosaminoglycans, and may act as a co-receptor for FGF signaling through FGFR1, which also requires interaction with heparan-sulfate glycosaminoglycans for receptor activation. Mutations in the genes encoding heparan-sulfate 6-*O*-sulfotransferase 1, an enzyme involved in glycosaminoglycan modifications, WDR11, an intracellular protein that interacts with the transcription factor EMX1, and semaphorin 3A, a secreted protein involved in axonal pathfinding, have also been found in some KS patients. Mutations in the chromodomain helicase DNA-binding protein 7 gene (*CHD7*) are present in approximately 70% of the patients affected by the CHARGE syndrome, which in most patients includes KS (Pinto et al., [@B40]), and mutations in this gene have been found in some patients who initially presented with KS. Finally, mutations in *PROKR2* and *PROK2*, encoding prokineticin receptor-2 and prokineticin-2, respectively, have been identified in approximately 9% of the KS patients, both in heterozygous and in homozygous or compound heterozygous states.

###### 

**KS genes**.

  Genes                                    *KAL1*                                                                      *FGFR1* and *FGF8*                                                 *PROKR2* and *PROK2*                        *CHD7*                                          *WDR11*               *HS6ST1*                   *SEMA3A*
  ---------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------- ----------------------------------------------- --------------------- -------------------------- -------------------------------------------------
  Mode(s) of transmission                  X-linked recessive                                                          Autosomal dominant (incomplete penetrance) or digenic/oligogenic   Autosomal recessive or digenic/oligogenic   ?                                               ?                     digenic/oligogenic?        digenic/oligogenic?
  Strategy for gene identification         Cytogenetics                                                                Cytogenetics and mouse model                                       Mouse models                                Candidate gene                                  Cytogenetics          *C. elegans* model         Mouse model
  Prevalence of mutations in KS patients   8% of male patients                                                         10 and \<1%                                                        7 and 3%                                    1--5%                                           \<1%                  \<1%                       6%
  Reference                                Legouis et al. ([@B27]), Franco et al. ([@B14]), Hardelin et al. ([@B17])   Dodé et al. ([@B11]), Falardeau et al. ([@B13])                    Dodé et al. ([@B12])                        Kim et al. ([@B25]), Jongmans et al. ([@B20])   Kim et al. ([@B24])   Tornberg et al. ([@B53])   Hanchate et al. ([@B16]), Young et al. ([@B55])

*?, not known*.

Prokineticins and Their Receptors
=================================

Prokineticins are secreted cysteine-rich proteins that possess diverse biological activities. The first identified member of this family was isolated from the venom of the black mamba snake (Joubert and Strydom, [@B21]), and was named mamba intestinal toxin 1 (MIT1) owing to its ability to induce intestinal contraction (Schweitz et al., [@B48]). Then, a small protein of similar size (77 amino acid residues, 8 kDa), with 58% sequence identity with MIT1, was isolated from skin secretions in the amphibian *Bombina variegata*, and called Bv8 (Mollay et al., [@B36]). Soon after, two mammalian proteins of this family were identified and named prokineticin-1 and -2 (PROK1 and PROK2) (Li et al., [@B31]; Kaser et al., [@B23]). PROK1 has 80% sequence identity with MIT1 and 58% identity with PROK2 (Li et al., [@B31]). The amino-terminal domain of prokineticins contains a sequence of six amino acid residues (AVITGA), which is conserved in all mammalian and non-mammalian orthologs. Substitutions, deletions, or insertions to this hexapeptide result in the loss of agonist activity on prokineticin receptors (Kaser et al., [@B23]; Bullock et al., [@B4]). The carboxy-terminal region of prokineticins contains 10 cysteine residues forming five disulfide bonds. Apart from its potent effect on gastrointestinal smooth muscle contraction, PROK1 was also characterized as an angiogenic factor with specific effects on steroidogenic glands, thus earning its initial name EG-VEGF (endocrine gland vascular endothelial growth factor) (LeCouter et al., [@B26]). Mouse and human orthologs of Bv8, also known as PROK2, have been involved in a variety of biological activities, including effects on neuronal survival, gastrointestinal smooth muscle contraction (Li et al., [@B31]), circadian locomotor rhythm (Cheng et al., [@B7]), survival and migration of adrenal cortical capillary endothelial cells (LeCouter et al., [@B26]). PROK2 also has a role in appetite regulation and its anorectic effect is mediated partly by the melanocortin system (Gardiner et al., [@B15]).

Prokineticins can bind to two different G protein-coupled receptors, prokineticin receptor-1 and -2 (PROKR1 and PROKR2), which have about 85% sequence identity. These receptors were characterized simultaneously by three different groups (Lin et al., [@B32]; Masuda et al., [@B34]; Soga et al., [@B50]). Both are able to bind to PROK1 and PROK2 with similar nanomolar range affinities. They have a central core formed by seven transmembrane α-helical segments (TM1--TM7) connected by intracellular (i1--i3) and extracellular (e1--e3) loops, an extracellular amino-terminal end, and an intracellular carboxy-terminal end. These plasma membrane receptors operate as molecular switches to relay extracellular ligand-activation to intracellular heterotrimeric G proteins. PROKR1 is mainly expressed in peripheral tissues, including endocrine glands and organs of the reproductive system, the gastrointestinal tract, lungs, and the circulatory system (Soga et al., [@B50]; Battersby et al., [@B3]), whereas PROKR2 shows relatively localized distribution in the central nervous system (Cheng et al., [@B7]; Lin et al., [@B32]).

The olfactory bulb is one of the few areas in the mammalian brain that produce neurons throughout life. New interneurons originating from progenitors in the subventricular zone (SVZ) are continually added to the olfactory bulbs. The mRNAs of both receptors (PROKR1 and PROKR2) are expressed in the SVZ and the olfactory bulbs. The expression of PROKR1 have been detected in these areas although less abundantly than PROKR2. Whereas PROK1 mRNAs were not detected in any of these brain region (Ng et al., [@B39]). It was first shown that PROK2 functions as a chemoattractant for these neuronal progenitors, which follow a rostral migratory stream. Accordingly, PROK2 deficiency in mice leads to a loss of normal olfactory bulb architecture, and accumulation of neuronal progenitors in the rostral migratory stream (Ng et al., [@B39]). Soon after, it was found that *Prokr2^−/−^* knockout mice exhibit early hypoplasia of the olfactory bulbs and severe atrophy of the reproductive organs in both sexes, a phenotype reminiscent of the KS features. In addition, immunohistochemical analysis of these mice revealed that the neuroendocrine GnRH cells were absent from the hypothalamus (Matsumoto et al., [@B35]).

*PROK2* is a clock-controlled gene: the level of its messenger RNA shows a circadian oscillation profile in the suprachiasmatic nuclei (Cheng et al., [@B7]; Li et al., [@B29]). It has been postulated that PROK2 signaling through PROKR2 is a suprachiasmatic nuclei clock output signal that regulates circadian rhythms (Prosser et al., [@B42]; Li et al., [@B30]). PROK2-null mice show accelerated acquisition of food anticipatory activity during a daytime food restriction (Li et al., [@B29]), exhibit reduced total sleep time predominantly during the light period, and also have an impaired response to sleep disturbance (Hu et al., [@B18]).

PROK2 is a functional target gene of proneural basic helix-loop-helix (bHLH) factors. Neurogenin-1 (NGN1) and MASH1 activate *PROK2* transcription by binding to E-box motifs on the *PROK2* promoter with the same set of E-boxes critical for another pair of bHLH factors, CLOCK and BMAL1, in the regulation of circadian clock (Cheng et al., [@B7]; Zhang et al., [@B56]).

Complex Genetics of Kallmann Syndrome Caused by Mutations in *PROKR2* or *PROK2*
================================================================================

We first considered that *PROKR2* was a relevant KS candidate because of the KS-like phenotype of PROKR2-null mice (see above). We thus sequenced the two coding exons of *PROKR2* in a cohort of patients affected by KS, and identified 10 different mutations (one frame-shifting and nine missense mutations) in 14 patients, either in heterozygous state (10 cases) or in homozygous or compound heterozygous state (4 cases) (Dodé et al., [@B12]) (Table [2](#T2){ref-type="table"}). Notably, most of these mutations were missense mutations, and many were also found in apparently unaffected individuals, thus initially raising some questions regarding their pathogenic role. A deleterious effect on the signaling activity of PROKR2 was, however, confirmed in transfected HEK-293 cells for most of the mutations (Cole et al., [@B8]; Monnier et al., [@B37]).

###### 

***PROKR2* and *PROK2* mutations in Kallmann syndrome**.

  Exon           Nucleotide change   Amino acid change   Localization (domain)          Functional consequence              Reference
  -------------- ------------------- ------------------- ------------------------------ ----------------------------------- ----------------------------------------------------------------------------------------------
  ***PROKR2***                                                                                                              
  1              58del               Frameshift          N-terminal region              NMD or protein truncation           Dodé et al. ([@B12])
                 151G \> A           A51T                N-terminal region              None?                               Reynaud et al. ([@B45]), Sbai et al. (unpublished)
                 238C \> T           R80C                First intracellular loop       None?                               Abreu et al. ([@B1]), Sbai et al. (unpublished)
  --             253C \> T           R85C                --                             Mild G protein-coupling defect      Cole et al. ([@B8]), Monnier et al. ([@B37]), Sarfati et al. ([@B46])
  --             253C \> G           R85G                --                             Strong G protein-coupling defect    Sarfati et al. ([@B46]), Raivio et al. ([@B43])
  --             254G \> T           R85L                --                             Mild protein-coupling defect        Sarfati et al. ([@B46]), Sbai et al. (unpublished)
  --             254G \> A           R85H                --                             Mild G protein-coupling defect      Dodé et al. ([@B12]), Monnier et al. ([@B37])
  --             337T \> C           Y113H               First extracellular loop       Strong G protein-coupling defect    Cole et al. ([@B8]), Sbai et al. (unpublished)
  --             343G \> A           V115M               --                             Strong G protein-coupling defect    Cole et al. ([@B8]), Sbai et al. (unpublished)
                 349C \> T           R117W               --                             Strong G protein-coupling defect    Sbai et al. (unpublished)
  --             420C \> G           Y140X               Third transmembrane domain     NMD or protein truncation           Abreu et al. ([@B1])
  2              491G \> A           R164Q               Second intracellular loop      Mild G protein-coupling defect      Dodé et al. ([@B12]), Cole et al. ([@B8]), Monnier et al. ([@B37])
  --             518T \> G           L173R               Fourth transmembrane domain    Cell surface-targeting defect       Dodé et al. ([@B12]), Abreu et al. ([@B1]), Cole et al. ([@B8]), Monnier et al. ([@B37])
  --             533G \> C           W178S               --                             Cell surface-targeting defect       Dodé et al. ([@B12]), Cole et al. ([@B8]), Monnier et al. ([@B37])
  --             563C \> T           S188L               --                             Strong G protein-coupling defect    Cole et al. ([@B8]), Sbai et al. (unpublished)
  --             604A \> G           S202G               Second extracellular loop      ?                                   Chan et al. ([@B5])
  --             629A \> G           Q210R               --                             Ligand-binding defect               Dodé et al. ([@B12]), Monnier et al. ([@B37])
                 701G \> A           G234D               Fifth transmembrane domain     Cell surface-targeting defect       Sbai et al. (unpublished)
  --             743G \> A           R248Q               Third intracellular loop       None?                               Cole et al. ([@B8])
  --             752G \> T           W251L               --                             Strong G protein-coupling defect?   Sarfati et al. ([@B46]), Sbai et al. (unpublished)
  --             802C \> T           R268C               --                             G protein-coupling defect?          Dodé et al. ([@B12]), Abreu et al. ([@B1]), Monnier et al. ([@B37]), Sarfati et al. ([@B46])
  --             T820 \> A           V274D               Sixth transmembrane domain     Strong G protein-coupling defect    Sinisi et al. ([@B49]), Sbai et al. (unpublished)
  --             868C \> T           P290S               --                             Cell surface-targeting defect       Dodé et al. ([@B12]), Monnier et al. ([@B37])
  --             969G \> A           M323I               Seventh transmembrane domain   None?                               Dodé et al. ([@B12]), Monnier et al. ([@B37])
  --             989del              Frameshift          --                             NMD or protein truncation           Sarfati et al. ([@B46])
  --             991G \> A           V331M               --                             Mild G protein-coupling defect      Dodé et al. ([@B12]), Cole et al. ([@B8]), Monnier et al. ([@B37]), Sarfati et al. ([@B46])
  --             1069C \> T          R357W               C-terminal region              None?                               Cole et al. ([@B8]), Sbai et al. (unpublished)
  ***PROK2***                                                                                                               
  1              −4C \> A                                Translation initiation site    Reduced protein synthesis?          Dodé et al. ([@B12])
  --             70G \> C            A24P                Signal peptide                 ?                                   Cole et al. ([@B8])
  --             94G \> C            G32R                AVITGA motif                   Strongly impaired activity?         Dodé et al. ([@B12])
  2              101 G \> A          C34Y                Cysteine-rich region           Strongly impaired activity          Cole et al. ([@B8])
  --             137G \> A           C46Y                Cysteine-rich region           ?                                   Dodé et al. (unpublished)
  --             150C \> G           I50M                --                             None?                               Cole et al. ([@B8])
  --             161G \> A           S54N                --                             ?                                   Sarfati et al. ([@B46])
  --             163del              Frameshift          --                             NMD or protein truncation           Pitteloud et al. ([@B41]), Leroy et al. ([@B28])
  --             217C \> T           R73C                --                             Strongly impaired activity          Dodé et al. ([@B12]), Leroy et al. ([@B28]), Cole et al. ([@B8])
  4              297_298insT         Frameshift          --                             NMD or protein truncation           Dodé et al. ([@B12]), Abreu et al. ([@B1])
                 301C \> T           R101W               --                             ?                                   Dodé et al. (unpublished)
  --             302G \> A           R101Q               --                             ?                                   Dodé et al. (unpublished)
  --             310C \> T           H104Y               --                             ?                                   Sarfati et al. ([@B46])

*Mutations reported in *PROKR2* and *PROK2* are mainly missense mutations. In most patients, the mutations have been found in heterozygous state. The R85C, R85H, R164Q, L173R, and P290S *PROKR2* mutations, as well as R73C, c.163del, and c.297_298insT *PROK2* mutations have, however, been found both in heterozygous and homozygous (or compound heterozygous) states, which suggests that patients heterozygous for *PROKR2* or *PROK2* mutations carry additional mutations, presumably in other, as yet unidentified Kallmann syndrome genes in most cases. Notably, two such patients have the L173R mutation in *PROKR2* together with S396L or R423X mutations in *KAL1* (Dodé et al., [@B12]; Sarfati et al., [@B46]), another patient has the V115M mutation in *PROKR2* together with the A24P mutation in *PROK2* (Cole et al., [@B8]), and still another patient has the R85L mutation in *PROKR2* together with a A604T mutation in *FGFR1* (Sarfati et al., [@B46]). In addition, the patient who has the S202G mutation in *PROKR2* also has I239T and R31C monoallelic mutations in *FGFR1* and *GNRH1*, respectively (Chan et al., [@B5]). Finally, two patients who carry R268C and V331M mutations in *PROKR2* also carry A189T and R240Q monoallelic mutations in *KISS1R* and *GNRHR*, respectively (Sarfati et al., [@B46]). Abbreviation: NMD, nonsense-mediated mRNA decay*.

*?, not known*.

Then, we considered the possibility that mutations in *PROK2* also account for some KS cases, especially since mutant mice defective in PROK2 showed a marked reduction in the size of their olfactory bulbs. *PROK2* contains four coding exons (Bullock et al., [@B4]), of which exon 3, encoding an arginine- and lysine-rich peptide of 21 amino acid residues, may or may not be included in the mature transcript due to alternative splicing (Wechselberger et al., [@B54]) (Figure [1](#F1){ref-type="fig"}). We sequenced the entire coding sequence of *PROK2* in the patients, and identified four different point mutations (two missense mutations, one frame-shifting mutation, and one single nucleotide substitution in the translation initiation sequence), all in the heterozygous state (Dodé et al., [@B12]). *PROK2* mutations in homozygous state were subsequently found in a few patients, and a KS-like phenotype was concomitantly reported in PROK2-null mutant mice (Pitteloud et al., [@B41]; Leroy et al., [@B28]). Since then, additional mutations in *PROKR2* and *PROK2* have been reported in KS patients. A list of the mutations, together with the corresponding references, is provided in Table [2](#T2){ref-type="table"}.

![**PROK2 gene structure and amino acid sequence**. The green box and green amino acid sequence denote the alternative exon and encoded peptide, respectively. The AVITGA motif is shown in red, and the 10 cysteinyl residues (forming five disulfide bonds) are in blue. Vertical arrows indicate the positions of the mutations identified in the patients.](fendo-04-00019-g001){#F1}

The finding, for given *PROKR2* and *PROK2* mutations, of both heterozygous and homozygous (or compound heterozygous) unrelated patients is quite remarkable, and argues in favor of a digenic or oligogenic mode of inheritance in heterozygous patients. To date, digenic inheritance of KS has been shown in few patients who had monoallelic missense mutations both in *PROKR2* or *PROK2*, and in other KS genes (*KAL1*, *FGFR1*) or genes underlying normosmic congenital hypogonadotropic hypogonadism (*GNRHR*, *KISS1R*) (Dodé et al., [@B12]; Cole et al., [@B8]; Raivio et al., [@B44]; Martin et al., [@B33]; Sarfati et al., [@B46]). The other patients harboring monoallelic mutations in *PROKR2* or *PROK2* are expected to carry at least one additional pathogenic mutation in as yet uncharacterized genes. Indeed, mutations in any of the currently known KS genes have been identified in only 30% of all KS patients, thus indicating that other disease genes remain to be discovered. Notably, it has been found that patients carrying biallelic mutations in *PROKR2* or *PROK2* consistently have a severe, complete KS phenotype, whereas the phenotype of patients carrying monoallelic mutations in these genes is more variable, and likely depends on the additional genetic hits in these patients (Martin et al., [@B33]; Sarfati et al., [@B46]).

Kallmann syndrome patients who carry biallelic mutations in *PROK2* or *PROKR2* do not seem to have any of the non-olfactory, non-reproductive occasional anomalies that have been reported in the previously characterized genetic forms of the disease (i.e., X-linked KAL1 form and autosomal dominant KAL2 form), specifically, bimanual synkinesis, renal agenesis, dental agenesis, and cleft lip or palate, and even though sleep disorders or increased body mass index have been reported in some of these patients, there is so far no evidence that these clinical features can be ascribed to the *PROKR2* and *PROK2* mutations, despite potential roles of these genes in sleep-wake regulation and ingestive behavior (see above). In addition, plasma cortisol levels were measured during 24 h in five patients mutated in *PROK2* or *PROKR2*, including one patient with biallelic *PROKR2* mutations, and normal circadian variation was observed in all cases (Sarfati et al., [@B46]), which argues against a major contribution of PROK2/PROKR2 signaling to physiological circadian variation of plasma cortisol levels in humans. Of course, this result does not exclude the presence of more subtle defects in the patients.

Consequences of the *PROKR2* and *PROK2* Missense Mutations on Receptor Signaling Activity
==========================================================================================

A total of 24 *PROKR2* missense mutations have been identified (Dodé et al., [@B12]; Cole et al., [@B8]; Sinisi et al., [@B49]; Chan et al., [@B5]; Abreu et al., [@B1]; Sarfati et al., [@B46]) in KS patients (Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). Most of the mutant receptors have been characterized regarding their ability to induce intracellular release of calcium upon PROK2-stimulation, their cell surface expression, and their PROK2-binding, in mammalian cell lines (Cole et al., [@B8]; Monnier et al., [@B37]; Abreu et al., [@B2]; Raivio et al., [@B43]; Sbai et al., in preparation). Although PROKR2 can activate different G protein pathways (Lin et al., [@B32]; Soga et al., [@B50]; Chen et al., [@B6]), its coupling to Gq, leading to intracellular release of calcium, represents the best characterized transduction mechanism. Only five mutants (A51T, R80C, R248Q, M321I, R357W) have properties similar to the wild-type PROKR2, thus calling into question the pathogenic effect of these missense variants. Notably, the R268C mutation has also been found in heterozygous state in a relatively large proportion (174 out of 2203, i.e., 7.9%) of individuals from the African American general population, and in homozygous state in six individuals from the same population (0.3%; see Exome Variant Server website URL: <http://evs.gs.washington.edu/EVS/>). Moreover, a clear deleterious effect of the R268C mutation on PROKR2 signaling through Gq protein activation could not be found in transfected HEK-293 cells, thus calling into question the pathogenic effect of this missense variant too. Most of the *PROKR2* mutations, however, impair cell surface expression, ligand-binding, or G protein-binding of the receptor (Figure [2](#F2){ref-type="fig"}). Three mutations affecting conserved residues located in the middle of the transmembrane helices, W178S, G234D, and P290S, impede targeting of the receptor to the cell surface. The Q210R mutant receptor is present at the cell surface, but is not able to bind to the ligand. The other mutants impair, either mildly or strongly, intracellular release of calcium in the Gq signaling pathway, and for some of them this effect might be due to the low expression of the mutant at the cell surface. Interestingly, the mutations that mostly impair the signaling are located nearby the extracellular side or the intracellular side of the receptor, and for these mutants, the loss-of-function is associated to a loss of cell surface expression. The mutations that result in a mildly impaired signaling activity are located in the intracellular loops, in agreement with the important role played by these loops in G protein-coupling. In addition, when wild-type and mutant receptors were coexpressed in HEK-293 cells, none of the mutant receptors that were retained within the cells did affect cell surface-targeting of the wild-type receptor, and none of the mutant receptors properly addressed at the plasma membrane did affect wild-type receptor signaling activity. This argues against a dominant negative effect of the mutations *in vivo*.

![**Positions of missense mutations in PROK2 and PROKR2 in the structural models of the ligand and the receptor**. The mutations are classified in different categories according to their effects on PROKR2 signaling activity: similar to wild-type (green), absence of the receptor at the cell surface (brown), absence of ligand-binding (blue), and strong or mild effect on signaling (red and orange, respectively). The mutations for which functional data are not available are denoted in black. The colored balls indicate the atom of alpha carbon of the polypeptidic chain of the mutated residue. Note that residue R357 is located in the proximal part of the C-terminal region of the receptor.](fendo-04-00019-g002){#F2}

A total of 10 missense mutations have been identified in PROK2 (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}) (Dodé et al., [@B12]; Cole et al., [@B8]; Leroy et al., [@B28]; Sarfati et al., [@B46]). A mutation located at the translation initiation site (−4C \> A) likely reduced the protein synthesis. Mutations of conserved residues in prokineticins are expected to strongly impair PROK2 activity such as those in the N-terminal conserved region AVITGA important for prokineticin activity (G32R), and those of the conserved cysteines (C34Y and C46Y). In addition, mutations that introduce an additional cysteine (R73C) in the cysteine-rich region of PROK2 may affect folding of the hormone then leading to a loss-of-function. This is consistent with the functional analysis of Cole et al. ([@B8]) who have examined the signaling properties of three PROK2 mutants: the C34Y and R73C mutations totally abolished and strongly impaired the intracellular calcium release activity of PROKR2, respectively, whereas the I50M mutation had an activity similar to that of the wild-type PROK2. The functional consequence of the other mutations (A24P, S54N, R101Q, R101W, and H104Y) are more difficult to predict in the absence of model of the complex between PROK2 and PROKR2. Further studies will be necessary to better analyze whether the mutations in PROK2 affect the process of binding and/or activation of PROKR2 by the hormone.

Conclusion
==========

The characterization of new genes involved in KS is a difficult goal. Because of the hypogonadotropic hypogonadism, sizes of the KS families are small and the mode of inheritance is very often difficult to establish. Animal models in which a gene has been inactivated and involving a KS phenotype are an alternative approach for the identification of new KS genes. The inactivation of *PROK2* or *PROKR2* lead to defective olfactory morphogenesis and hypogonadism in mice and humans. Curiously, *PROK2* and *PROKR2* mutations in homozygous state were found in a few patients and the main part of the KS patients carried only heterozygous mutations. In all of the functional studies done so far, only Gq signaling pathways have been investigated to characterize the PROK2 and PROKR2 mutants and further studies will be necessary to analyze other signaling pathways. Interestingly, few patients who had monoallelic missense mutations both in *PROK2* or *PROKR2*, and in other KS or normosmic congenital hypogonadotropic hypogonadism genes, raising the idea of oligogenism. So far, this hypothesis has been validated only in a few patients suggesting that the second mutation in the other heterozygous patients resides in unexplored regions of the genes or as yet undiscovered KS genes.
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